RSS Precigen Announces Submission Of BLA For PRGN-2012 - Quick Facts

Currently reading:
 RSS Precigen Announces Submission Of BLA For PRGN-2012 - Quick Facts

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
9,822
Likes
1,923
Credits
33,507©
Cash
0$
Precigen (PGEN) has finalized the rolling submission of a Biologics License Application (BLA) to the FDA for PRGN-2012, aimed at treating adult patients with recurrent respiratory papillomatosis. This submission is currently within the FDA's initial 60-day review phase, during which the agency will determine whether to accept the BLA for full evaluation and establish the PDUFA action date. The application also requests priority review status.

Helen Sabzevari, the CEO of Precigen, commented, "Following our recently announced financial transactions, which strengthen our balance sheet, we have secured our financial runway through 2026. This positions us well for a potential commercial launch in the latter half of 2025."

PRGN-2012 is an investigational AdenoVerse gene therapy, aiming to induce immune responses against cells infected with human papillomavirus strains HPV 6 or HPV 11.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom